ESR1 and breast adenocarcinoma: Djurendić et al. described the synthesis of some 17α-picolyl- and 17-picolylideneandrost-5-ene derivatives and their antiaromatase and antitumor activity against the ER+ human breast adenocarcinoma MCF-7, and ER- human breast adenocarcinoma MDA-MB231, and PC-3 prostate cancer cell lines.